Want to see ABOS full AI Analyst Report?
ABOS Stock Chart & Stats
$2.82
-$0.08(-4.37%)
At close: 4:00 PM EST
$2.82
-$0.08(-4.37%)
Day’s Range― - ―
52-Week Range$1.19 - $3.60
Previous CloseN/A
Volume101.31K
Average Volume (3M)595.83K
Market Cap
$162.51M
Enterprise Value$51.96
Total Cash (Recent Filing)$128.40M
Total Debt (Recent Filing)$31.16M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Aug 17, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding72,227,580
10 Day Avg. Volume384,529
30 Day Avg. Volume595,833
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Oligomer-targeting Mechanism With KOL SupportSabirnetug's selective targeting of soluble amyloid‑beta oligomers addresses a biologically plausible toxic species and is viewed as mechanistically distinct from existing anti‑amyloid agents. Strong KOL interest improves chances of clinical adoption, investigator support and payer engagement if pivotal data confirm benefit.
Enhanced Brain Delivery (EBD) Program Shows Large Exposure GainsEBD candidates achieving 14–40x brain exposure materially change the drug delivery profile, enabling higher CNS exposure and potential subcutaneous dosing. These durable technical gains can widen therapeutic window, support differentiation versus rivals, and create a platform extension beyond the lead antibody.
Strengthened Liquidity From March 2026 Private PlacementA larger cash balance and recent financing reduce immediate dilution pressure and allow the company to complete ALTITUDE‑AD and IND‑enabling EBD work. While runway is finite, the funding materially increases near‑term operational flexibility and supports key program milestones into early 2027.
Bears Say
No Commercial Revenue And Persistent Net LossesBeing pre‑commercial with no product revenue means Acumen must rely on capital markets to fund R&D. Persistent, widening losses consume equity and amplify dilution risk over time, limiting the firm's ability to self‑fund growth or withstand extended development setbacks without recurring financings.
High Cash Burn With Limited RunwaySustained negative free cash flow at ~‑$100M TTM creates structural funding dependence; although cash was bolstered in March 2026, management projects runway only into early 2027. This forces near‑term capital raises that can dilute shareholders and constrain long‑term strategic options if trials or IND timelines slip.
Binary Phase II Outcome And Dose/regulatory UncertaintyThe company's trajectory hinges on a single phase II readout; a negative outcome would impair both registration strategy and partner interest. Dose selection, ARIA safety profile and class skepticism remain unresolved, making commercialization efforts and EBD development contingent on that binary result.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals, Inc.’s price range in the past 12 months?
Acumen Pharmaceuticals, Inc. lowest stock price was $1.19 and its highest was $3.60 in the past 12 months.
What is Acumen Pharmaceuticals, Inc.’s market cap?
Acumen Pharmaceuticals, Inc.’s market cap is $162.51M.
When is Acumen Pharmaceuticals, Inc.’s upcoming earnings report date?
Acumen Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were Acumen Pharmaceuticals, Inc.’s earnings last quarter?
Acumen Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.403 by $0.073.
Is Acumen Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Acumen Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Acumen Pharmaceuticals, Inc. pay dividends?
Acumen Pharmaceuticals, Inc. does not currently pay dividends.
What is Acumen Pharmaceuticals, Inc.’s EPS estimate?
Acumen Pharmaceuticals, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Acumen Pharmaceuticals, Inc. have?
Acumen Pharmaceuticals, Inc. has 72,227,580 shares outstanding.
What happened to Acumen Pharmaceuticals, Inc.’s price movement after its last earnings report?
Acumen Pharmaceuticals, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.403. Following the earnings report the stock price went down -3.502%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (183.69% Upside)
$8.00 (183.69% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 6.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $89.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.02%
12-Months-Change
Fundamentals
Return on Equity
-123.07%
Trailing 12-Months
Asset Growth
-34.65%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
ABOS Stock 12 Month Forecast
Average Price Target
$8.00
▲(183.69% Upside)
Technical Analysis
Ownership Overview
32.76% Insiders
5.71% Mutual Funds
0.02% Other Institutional Investors
56.22% Public Companies and
Individual Investors